Literature DB >> 7984525

[Measurement of quality of life in intermittent claudication. Clinical validation of a questionnaire].

P Marquis1, C Fayol, C McCarthy, J N Fiessinger.   

Abstract

OBJECTIVES: Functional limitation in patients with intermittent claudication impairs their quality of life. In order to measure this new evaluation parameter, we developed a self-administered questionnaire: Artemis.
METHODS: The questionnaire was composed of a general instrument (SF-36) and a specific one. A cross sectional study was performed in 177 patients with intermittent claudication (mean age 68 +/- 10 years, 77% males) who stated their walking distance was limited within 50 to + 2000 meters. The acceptability, reliability and sensitivity of the questionnaire were tested.
RESULTS: In patients who had a walking distance greater than 500 m (n = 96), the scores obtained were significantly higher (better quality of life) than in patients whose walking distance was limited to less than 500 m (n = 81) (p < 0.05). Intermittent claudication had a global effect on the different parameters of the quality of life evaluated by the questionnaire including physical performance and psychological and social aspects.
CONCLUSION: The Artemis questionnaire as shown its ability to describe patients with intermittent claudication. It can be used in clinical trials as a tool for measuring quality of life.

Entities:  

Mesh:

Year:  1994        PMID: 7984525

Source DB:  PubMed          Journal:  Presse Med        ISSN: 0755-4982            Impact factor:   1.228


  6 in total

Review 1.  Patient-reported physical activity questionnaires: a systematic review of content and format.

Authors:  Kate Williams; Anja Frei; Anders Vetsch; Fabienne Dobbels; Milo A Puhan; Katja Rüdell
Journal:  Health Qual Life Outcomes       Date:  2012-03-13       Impact factor: 3.186

2.  Intermittent claudication: pharmacoeconomic and quality-of-life aspects of treatment.

Authors:  Gregorio Brevetti; Roberta Annecchini; Roxanna Bucur
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

Review 3.  [Quality of life and peripheral obliterative arteriopathy. Perspective for the future].

Authors:  P Priollet
Journal:  Drugs       Date:  1998       Impact factor: 9.546

4.  [Quality of life of patient with peripheral arterial obliterative disease treated with ifenprodil tartrate. Results of an ARTEMIS study].

Authors:  P Marquis; M Lecasble; P Passa
Journal:  Drugs       Date:  1998       Impact factor: 9.546

Review 5.  [Evaluation of the impact of peripheral obliterative arteriopathy on quality of life].

Authors:  P Marquis
Journal:  Drugs       Date:  1998       Impact factor: 9.546

Review 6.  [Socioeconomic and quality of life repercussions of arterial hypertension].

Authors:  B Selke; P Marquis; T Lebrun
Journal:  Drugs       Date:  1998       Impact factor: 9.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.